TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15310351

Group type: EXPERIMENTAL
Intervention: Mouth opening test
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Thyromental distance test
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Head and neck movement test
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Mandibular luxation test
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Assessment of oropharyngeal view
Number of subjects: 2
Study: 11642624

Group type: EXPERIMENTAL
Intervention: 5 days of oral acyclovir treatment (80 mg/kg/day up to a maximum of 3,200 mg/day in four divided doses) starting within 24 hours of rash onset (Group A)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 5 days of acyclovir treatment starting on the first day of rash (Group B1)
Number of subjects: 177

Group type: COMPARATOR
Intervention: 5 days of acyclovir treatment starting on the second day of rash (Group B2)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Group A subjects (acyclovir treatment within 24 hours of rash onset)
Number of subjects: 177
Study: 9893537

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 93

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 93
Study: 9374086

Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2 at intervals of 30 minutes, 4 hours, and 24 hours every 3 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2
Number of subjects: 34
Study: 2628366

Group type: EXPERIMENTAL
Intervention: Resistance training 3 days/week for 10 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Resistance training 3 days/week for 18 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Resistance training 2 days/week for 10 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Resistance training 2 days/week for 18 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 117
Study: 791447

Group type: EXPERIMENTAL
Intervention: FAC-BCG
Number of subjects: 45

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 45
Study: 31649369

Group type: EXPERIMENTAL
Intervention: Active Guide brochure and additional documents, n=40
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group, n=40
Number of subjects: 86
Study: 28127672

Group type: EXPERIMENTAL
Intervention: Activated pillow
Number of subjects: 22
Study: 24916651

Group type: EXPERIMENTAL
Intervention: Epidural corticosteroids (DepoMedrol™)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 150
Study: 23148731

Group type: EXPERIMENTAL
Intervention: 200 mg lacosamide oral tablet
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 mg lacosamide oral syrup
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison of tablet and syrup formulations
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both formulations of lacosamide
Number of subjects: 16
Study: 22130748

Group type: EXPERIMENTAL
Intervention: Supervised treatment in out-patients for schizophrenia (STOPS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 110
Study: 19387363

Group type: EXPERIMENTAL
Intervention: Interval hypoxic training (15 sessions of passive intermittent hypoxia with 15-12% oxygen for 3-5 min periods)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normoxia (placebo group inhaled normoxic air)
Number of subjects: 18
Study: 16760210

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 15144935

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 2289
Study: 10641699

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) injections
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 9309953

Group type: EXPERIMENTAL
Intervention: Depressed group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-depressed participants
Number of subjects: 0
Study: 8506790

Group type: EXPERIMENTAL
Intervention: Structured Behavioral Change with nicotine gum (Group SBCN)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Structured Behavioral Change without nicotine gum (Group SBC)
Number of subjects: 450

Group type: COMPARATOR
Intervention: GP advice with nicotine gum (Group AN)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 450
Study: 3317337

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg b.i.d.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination of captopril and nifedipine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 26

Group type: COMPARATOR
Intervention: Combination of both drugs
Number of subjects: 26
Study: 29420951

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (subconjunctival injection)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Standard group (control)
Number of subjects: 213
Study: 26660000

Group type: EXPERIMENTAL
Intervention: Diode laser (DL) for de-epithelialization of free gingival graft (FGG) and palatal wound irradiation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group: De-epithelialized gingival grafts (DGG) using blade (DGG-B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both techniques (DGG-L and DGG-B)
Number of subjects: 52
Study: 24907185

Group type: COMPARATOR
Intervention: 120 kVp protocol
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 100 kVp protocol
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 80 kVp protocol
Number of subjects: 157
Study: 22901422

Group type: EXPERIMENTAL
Intervention: Daily pin site care
Number of subjects: 56

Group type: COMPARATOR
Intervention: No pin tract care
Number of subjects: 56
Study: 20339195

Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy (LVH) measured by SV1+ RV5
Number of subjects: 3230

Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy (LVH) classified at threshold values of 35 mm
Number of subjects: 3230

Group type: EXPERIMENTAL
Intervention: Electrocardiographic left ventricular hypertrophy (LVH) classified at threshold values of 40 mm
Number of subjects: 3230

Group type: EXPERIMENTAL
Intervention: Increasing SV1+ RV5 values
Number of subjects: 3230
Study: 18417560

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics intervention (n = 59)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group (n = 60)
Number of subjects: 504
Study: 15882256

Group type: EXPERIMENTAL
Intervention: AT1R blocker (losartan)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: AT1R blocker (candesartan)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: AT1R blocker treatment
Number of subjects: 21
Study: 11788564

Group type: EXPERIMENTAL
Intervention: Brachytherapy (10 Gy)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no further therapy)
Number of subjects: 22
Study: 10411764

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral midazolam premedication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sevoflurane with no premedication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral midazolam preoperatively with sevoflurane
Number of subjects: 100
Study: 7586401

Group type: EXPERIMENTAL
Intervention: Antegrade/retrograde cold blood cardioplegia (CBP, 23 patients)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Antegrade crystalloid cardioplegia (CCP, 21 patients)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Continuous retrograde warm blood cardioplegia (WBP, 20 patients)
Number of subjects: 64
Study: 2405271

Group type: EXPERIMENTAL
Intervention: Surgical resection of brain metastases followed by radiotherapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Needle biopsy and radiotherapy
Number of subjects: 48
Study: 352634

Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30968546

Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 302

Group type: COMPARATOR
Intervention: no-CTO PCI
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: successful CTO PCI
Number of subjects: 302

Group type: COMPARATOR
Intervention: failed/no-CTO PCI
Number of subjects: 302
Study: 28077221

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 47
Study: 25851802

Group type: EXPERIMENTAL
Intervention: Aprepitant (80 mg for 15-40 kg, 125 mg for 41-65 kg on day 1, 80 mg for days 2-3)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 23910768

Group type: EXPERIMENTAL
Intervention: Regular fat meal
Number of subjects: 191

Group type: COMPARATOR
Intervention: High fat meal
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Large meal
Number of subjects: 191

Group type: COMPARATOR
Intervention: Small meal
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Perceived similarity to the target
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 191
Study: 21528603

Group type: EXPERIMENTAL
Intervention: Auricular point‐sticking group (APS group, n=31)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo group (n=31)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Blank group (n=30)
Number of subjects: 92
Study: 19267731

Group type: EXPERIMENTAL
Intervention: Mobile phone-based advanced symptom management system (ASyMS)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 112
Study: 17026492

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg/day for 12 weeks
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 195
Study: 15126259

Group type: EXPERIMENTAL
Intervention: Chest radiography alone or in combination with sputum cytologic examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (unspecified screening methods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case-control studies from Japan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening methods (general)
Number of subjects: 0
Study: 11404278

Group type: EXPERIMENTAL
Intervention: Alcohol (total dose of 256 g)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9248820

Group type: EXPERIMENTAL
Intervention: Number-consonant mnemonic training (n = 17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo training (n = 19)
Number of subjects: 36
Study: 8485531

Group type: EXPERIMENTAL
Intervention: Low dose (D1) of Tacrine (40 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose (D2) of Tacrine (80 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (D0)
Number of subjects: 0
Study: 3315265

Group type: EXPERIMENTAL
Intervention: Euphyllin CR (642 mg total daily dose, 1/3 in the morning and 2/3 in the evening, evening dose at 2200 hr)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Afonilum Retard (500 mg total daily dose, equal amounts in the morning and evening, evening dose at 2000 hr)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29036504

Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride or losartan
Number of subjects: 110
Study: 27422692

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) - 20 mL bupivacaine/20 mL saline, intraoperative local infiltration
Number of subjects: 57

Group type: COMPARATOR
Intervention: Interscalene nerve block (INB), preoperative
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both LB and INB
Number of subjects: 57
Study: 24473100

Group type: EXPERIMENTAL
Intervention: Closed-loop control (fMRI activity in SPL and cerebellum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open-loop control (fMRI activity in IPL and prefrontal areas)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aiming movements with a stick
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aiming movements with a laser pointer
Number of subjects: 0
Study: 23584651

Group type: EXPERIMENTAL
Intervention: Bimatoprost (0.03 %)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Travoprost (0.004 %)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study: 20683094

Group type: EXPERIMENTAL
Intervention: Message tailored to physical activity as an expert-determined topic (expert)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Message tailored to physical activity as a participant-selected topic (choice)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Nontailored message (comparison)
Number of subjects: 408
Study: 18000088

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 312
Study: 16184062

Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg midazolam
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg midazolam
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg midazolam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group A (placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group D (1.0 mg/kg midazolam)
Number of subjects: 100
Study: 12626890

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI) users
Number of subjects: 1785

Group type: COMPARATOR
Intervention: Reverse transcriptase inhibitor (RTI) users
Number of subjects: 1785

Group type: COMPARATOR
Intervention: No antiretroviral therapy (ART) users
Number of subjects: 1785

Group type: COMPARATOR
Intervention: HIV-uninfected women
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1785
Study: 10384925

Group type: EXPERIMENTAL
Intervention: Scrubbing up with a brush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple hand washing without a brush
Number of subjects: 0
Study: 9295498

Group type: EXPERIMENTAL
Intervention: Multi-agent controlling method to promote milk secretion
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 280
Study: 1852848

Group type: EXPERIMENTAL
Intervention: Preventive treatment program (parent training and training of boys for social skills, fantasy play, and television viewing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreated group 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreated group 2
Number of subjects: 0
Study: 6660455

Group type: EXPERIMENTAL
Intervention: Thiopentone anesthesia
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Methohexitone anesthesia
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (nonoperated patients)
Number of subjects: 39
Study: 30704862

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 26
Study: 28382811

Group type: EXPERIMENTAL
Intervention: Outpatient NIV initiation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inpatient NIV initiation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NIV acceptance (>4 h/night)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: NIV adherence (>120 h/month)
Number of subjects: 50
Study: 25826334

Group type: EXPERIMENTAL
Intervention: 25g glucose drink
Number of subjects: 67

Group type: COMPARATOR
Intervention: Inert placebo drink
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High motivation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High levels of self‐control
Number of subjects: 67
Study: 23370827

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) associated with graduated compression stockings (GCS)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Graduated compression stockings (GCS) alone
Number of subjects: 407
Study: 21296248

Group type: EXPERIMENTAL
Intervention: IV paracetamol 15 mg/kg
Number of subjects: 64

Group type: COMPARATOR
Intervention: IV tramadol 1.0 mg/kg
Number of subjects: 64
Study: 19577902

Group type: EXPERIMENTAL
Intervention: Intranasal packing with septal splints and antibiotic meshes
Number of subjects: 114

Group type: COMPARATOR
Intervention: Trans-septum suturing without packing
Number of subjects: 114
Study: 17074346

Group type: EXPERIMENTAL
Intervention: Oral E(2) (oE(2), 1 mg/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Transdermal E(2) (tE(2), 0.05 mg/d)
Number of subjects: 50
Study: 15238023

Group type: EXPERIMENTAL
Intervention: Picture encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Word encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postrecall recognition test
Number of subjects: 0
Study: 11555457

Group type: EXPERIMENTAL
Intervention: Endometrial features assessed by transvaginal ultrasound
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Endometrial growth and its pattern transformation during stimulation
Number of subjects: 145
Study: 9594760

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (contralateral canine)
Number of subjects: 30
Study: 7950108

Group type: EXPERIMENTAL
Intervention: No-stitch technique
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sutured scleral wound closure
Number of subjects: 300
Study: 3661439

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg once or twice daily for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg plus amiloride 2.5 mg once or twice daily for 6 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg plus hydrochlorothiazide 25 mg and amiloride 2.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nisoldipine for an additional period of 6 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of low-dose nisoldipine and low-dose diuretic
Number of subjects: 32
Study: 30346497

Group type: EXPERIMENTAL
Intervention: Enhanced self-regulation condition (writing about stress and coping at week 1, deepest feelings at week 2, and finding benefits at week 3)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Self-regulation condition (writing about deepest feelings at week 1, stress and coping at week 2, and finding benefits at week 3)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Cancer-fact condition (writing about facts relevant to the cancer experience for three weeks)
Number of subjects: 136
Study: 28103616

Group type: EXPERIMENTAL
Intervention: l-Lysine (4.95 g/day orally)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25742208

Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg daily plus 25 mg targeted (at most daily) in anticipation of drinking
Number of subjects: 128

Group type: COMPARATOR
Intervention: Daily/targeted placebo
Number of subjects: 128
Study: 24304689

Group type: EXPERIMENTAL
Intervention: Specialist medical care plus the Lightning Process (LP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Specialist medical care
Number of subjects: 56
Study: 21234852

Group type: EXPERIMENTAL
Intervention: Prednisone (Cor, 50 mg/day for 7 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 9
Study: 18259123

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (titrated to 100 mg/d at 4 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metoprolol succinate 50 mg (titrated to 100 mg/d at 4 weeks)
Number of subjects: 36
Study: 16907691

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Etanercept treatment (efficacy data from RCT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (efficacy data from RCT)
Number of subjects: 2
Study: 14570732

Group type: EXPERIMENTAL
Intervention: Cluster analysis based on rectal sensitivity and psychological symptoms
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Psychosocial factors included in analysis
Number of subjects: 107
Study: 11105477

Group type: EXPERIMENTAL
Intervention: Training for lie detection; 2 days of training, with assessments before and after training.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Feedback group; received feedback on accuracy after each judgment.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Feedback + cue information group; received feedback and information on cues to deception.
Number of subjects: 32
Study: 9187779

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (ITF) 25 micrograms
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lumbar epidural analgesia (LEA) with epidural lidocaine 1.5%
Number of subjects: 24
Study: 1347230

Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1
Number of subjects: 16

Group type: COMPARATOR
Intervention: H1- and H2-receptor antagonists + Atracurium 0.6 mg kg‐1
Number of subjects: 16
Study: 4007349

Group type: EXPERIMENTAL
Intervention: Digoxin therapy (Group A)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No therapy (Group B)
Number of subjects: 24
Study: 31744458

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA-a)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythropoietin (EPO)
Number of subjects: 0
Study: 29193767

Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 27401884

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention program (nine lessons, 45 mins per week for 9 weeks)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Standard relaxation program (Relax)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Non-treatment control group
Number of subjects: 3000
Study: 24678758

Group type: EXPERIMENTAL
Intervention: Passive mobilization and stretching
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Manual orthopaedic therapy with proprioception training
Number of subjects: 9